Abstract: The present invention relates to a process for the solidification of hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate, DHHB), wherein the process comprises the step of (a) applying a shear rate of 800 s?1 or more to liquid hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate and (b) adding seed crystals of hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate.

Abstract: The present invention relates to a process for the solidification of hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate, DHHB), wherein the process comprises the step of (a) applying a shear rate of less than 800 s?1 to liquid hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate and (b) adding seed crystals of hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate.

Abstract: A propulsion assembly for an aircraft comprising a dual-flow turbine engine equipped with a fan, an aerodynamic outer shroud acting as a nacelle as well as a mounting pylon, the propulsion assembly having a secondary flow path defined by an outer radial defining surface formed by the shroud, the turbine engine including stator vanes, and the mounting pylon comprising a part housed in the secondary flow path, referred to as upstream part. According to the invention, the upstream part of the pylon extends radially from the inner radial defining surface, along a radial pylon height strictly less than a total radial height of the secondary flow path, and the upstream part of the pylon extends in the downstream direction from a root part of one of the stator vanes.

Abstract: An aircraft turbojet engine extending along an X axis and comprising a blower configured to provide a reverse thrust and a nacelle comprising an air intake which comprises at least one deflection member movably mounted between a deployed position in which the deflection member projects from the inner wall or from the lip of the air intake in a radially inward direction of deployment facing the X axis or in a longitudinal direction of deployment with respect to the X axis, in order to allow a release of the reverse air flow from the inner wall to support the reverse thrust phase, and a retracted position in which the air intake has an aerodynamic profile so as to guide the internal air flow along the inner wall in order to support the thrust phase.

Abstract: The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.

Abstract: The invention relates to the novel therapeutically valuable enantiomer-pure [3a?,8b?]-1,2,3a,4,8b-hexahydropyrrolocyclopentapyridine derivatives of the general formula (I), wherein Z is a single bond or CH2, R1 represents hydrogen or a straight-chain or branched, optionally unsaturated lower alkyl group which may be perfluorated, R2 and R3 independently represent hydrogen, a straight-chain or branched, optionally unsaturated lower alkyl group which may be perfluorated, lower alkoxy, lower alkylthio or halogen, and X and Y alternatively represent CH or N. The invention also relates to the pharmaceutical salts thereof, to a method for their production and to their use.

Abstract: Methods of treating and/or preventing arteriosclerosis are disclosed. In certain methods, a composition containing at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid precursor protein (APP) is administered to a subject to treat and/or prevent arteriosclerosis in the subject.

Abstract: The invention relates to a method for producing isotopically labelled secondary metabolic products of fungi or bacteria in a liquid synthetic culture medium. According to said method, the synthesis is carried out by immobilizing the fungi or bacteria on an inert carrier, adding a liquid synthetic culture medium in which essentially all of the carbon atoms, nitrogen atoms and/or sulphur atoms are replaced by stable isotopes.

Abstract: The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.